John A. Thompson

powered by
COS Expertise®
University of Washington
School of Medicine
Medicine
Oncology
ProfessorAppointed: 2004
Fred Hutchinson Cancer Research Center
Clinical Research Division
Professional Headshot of John A. Thompson

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Avenue E., G3-200
Seattle, Washington 98109-1023
United States

Contact Information

Phone: (206) 288-1195
Fax: (206) 288-6210
jat@u.washington.edu

Qualifications

M.D., University of Alabama, 1979.
B.A., Davidson College, 1973.

Expertise and Research Interests

My clinical research interests focus on the immunotherapy of cancer with cytokines and activated lymphocytes. A partial listing of trials currently under my direction include:

I serve on the National Comprehensive Cancer Network Clinical Guidelines Committees for Melanoma and Occult Primary, the Southwest Oncology Group Melanoma and Lymphoma committees, and the Cytokine Working Group. I am a member of the American Joint Committee on Cancer working group for staging of melanoma. I am the current Secretary-Treasurer of the Washington State Medical Oncology Society.

Other Expertise

Honors/Awards:
Alpha Omega Alpha, 1978
Recipient, Clinical Investigator Award (NCI), 1985-1988

Keywords

COS Keywords:

Bone Marrow, Bone Marrow Transplantation, Cancer Or Carcinogenesis, Immunotherapy, Lymphoma, Oncology, Tumors.

Additional Terms:

Bone Marrow, Bone Marrow Transplantation, Cytokinesis, Immunotherapy, Interleukin-2, Lymphoma, Melanoma, Myelodysplastic Syndrome, Oncology, Renal Cell, Renal Cell Carcinoma, T-cell Clone, Tumor Biology.

Memberships

American Association for Cancer Research
American Society of Clinical Oncology
Society for Biological Therapy
Southwest Oncology Group
Washington State Medical Oncology Society

Previous Positions

1993-2004, Associate Professor, University of Washington, School of Medicine, Medicine, Oncology
1988-1993, Assistant Professor, University of Washington, Oncology
1985-1988, Acting Assistant Professor, University of Washington, Oncology
1982-1985, Fellow, University of Washington, Oncology
1982-1982, Chief Medical Resident, Providence Medical Center
1979-1982, Intern and Resident, University of Washington, Internal Medicine

Funding Received

  • Phase II trial of chemo-immunotherapy for patients with stage IV melanoma - Principal Investigator
  • Phase III trial of therapy with Melacine vaccine and interferon versus interferon for patients with Stage III melanoma- Co-Investigator
  • Phase I/II trial of lymphocytes activated by stimulation with antibody to CD3 and CD28 plus interleukin-2 for patients with Stage IV renal cell carcinoma Principal Investigator
  • Randomized Phase III trial of total body irradiation, cyclophosphamide, etoposide, and autologous peripheral blood stem cell transplantation followed by interleukin-2 versus observation for patients with relapsed or refractory non-Hodgkin’s lymphoma, a SWOG trial Principal Investigator

Publications

  • Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW, A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma, Clinical Cancer Research : an Official Journal of the American Association for Cancer Research., 9(10), 3562-70, September 2003 Abstract
  • Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF, New TNM melanoma staging system: Linking biology and natural history to clinical outcomes, Seminars in Surgical Oncology, 21(1), 43-52, 2003 Abstract
  • Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferre, Proceedings of the National Academy of Sciences of the United States of America., 99(25), 16168-73, December 2002 Abstract
  • Thompson JA, The revised American Joint Committee on Cancer staging system for melanoma, Seminars in Oncology, 29(4), 361-9, Aug 2002 Abstract
  • Masood N, Russell KJ, Olerud JE, Sabath DE, Sale GE, Doney KC, Flowers ME, Fefer A, Thompson JA, Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation, Journal of the American Academy of Dermatology, 47(1), 140-5, July 2002 Abstract
  • Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 20(8), 2058-66, April 2002 Abstract
  • Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH, Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group, Blood, 95(4), 1175-9, 2000 Abstract
  • Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS, Multicenter, randomized, phase III trial of CD8( ) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma, Journal of Clinical Oncology, 17(8), 2521-9, August 1999 Abstract
  • Thompson J A, Gold P J, Markowitz D R, Byrd D R, Lindgren C G, Fefer A, Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma, Cancer Journal From Scientific American, 3 Suppl 1, S29-34, December 1997 Abstract
  • Gold PJ, Thompson JA, Markowitz DR, Neumann S, Fefer A, Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2, Cancer Journal of the Scientific American, 3 Suppl 1, S85-91, December 1997 Abstract
  • Fefer A, Robinson N, Benyunes M C, Bensinger W I, Press O, Thompson J A, Lindgren C, Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies, Cancer Journal From Scientific American, 3 Suppl 1, S48-53, December 1997 Abstract
  • Gold P J, Thompson J A, Markowitz D R, Neumann S, Fefer A, Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2, Cancer Journal From Scientific American, 3 Suppl 1, S85-91, December 1997 Abstract
  • Mankoff D A, Thompson J A, Gold P, Eary J F, Guinee D G Jr, Samlowski W E, Identification of interleukin-2-induced complete response in metastatic renal cell carcinoma by FDG PET despite radiographic evidence suggesting persistent tumor., AJR American Journal of Roentgenology, 169(4), 1049-50, October 1997 Abstract
  • Yee C, Gilbert M J, Riddell S R, Brichard V G, Fefer A, Thompson J A, Boon T, Greenberg P D, Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus., Journal of Immunology, 157(9), 4079-86, 1 Nov 1996 Abstract
  • Gold P J, Fefer A, Thompson J A, Paraneoplastic manifestations of renal cell carcinoma., Seminars In Urologic Oncology, 14(4), 216-22, November 1996 Abstract
  • Massumoto C, Benyunes M C, Sale G, Beauchamp M, York A, Thompson J A, Buckner C D, Fefer A, Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy., Bone Marrow Transplantation, 17(3), 351-6, March 1996 Abstract
  • Robinson N, Sanders J E, Benyunes M C, Beach K, Lindgren C, Thompson J A, Appelbaum F R, Fefer A, Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia., Blood, 87(4), 1249-54, 15 Feb 1996 Abstract
  • Benyunes M C, Higuchi C, York A, Lindgren C, Thompson J A, Buckner C D, Fefer A, Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial., Bone Marrow Transplantation, 16(2), 283-8, August 1995 Abstract
  • Sosman J A, Flaherty L E, Liu P Y, Fletcher W, Thompson J A, Hantel A, Sondak V, A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study., Investigational New Drugs, 13(1), 83-7, 1995 Abstract
  • Benyunes MC, Thompson JA, York A, Buckner CD, Fefer A, Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies, Progress in Clinical and Biological Research, 389, 229-38, 1994 Abstract
  • Thompson JA, Benyunes MC, Bianco JA, Fefer A, Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells, Seminars in Oncology, 20(6 Suppl 9), 46-51, December 1993 Abstract
  • Pavletic Z, Benyunes MC, Thompson JA, Lindgren CG, Massumoto C, Alderson MR, Buckner CD, Fefer A, Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy, Experimental Hematology, 21(10), 1371-8, September 1993 Abstract
  • Thompson JA, Lindgren CG, Benyunes MC, Bianco JA, Shields AF, Fefer A, The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity, Journal of Immunotherapy : Official Journal of the Society for Biological Therapy., 13(2), 84-90, February 1993 Abstract
  • Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A, Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 10(6), 960-8, June 1992 Abstract
  • Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A, Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies, Blood, 77(12), 2561-8, June 1991 Abstract

Profile Details

Last Updated: 9/9/2004

COS Expertise ID #308655
Reference this profile directly: http://myprofile.cos.com/thompsoj55